Studie sucht Patient – Patient sucht Studie

Jatros

16.11.2022

Sie wollen Ihren Patienten in eine Studie einbringen? Hier finden Sie eine Auswahl aktueller nationaler und internationaler Studienprotokolle und deren Kontaktpersonen.

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676) (Sponsor: MSD)

Studien-Koordinatoren:
Dr. Stephan Korn
Universitätsklinik für Urologie
Medizinische Universität Wien
E-Mail: stephan.korn@meduniwien.ac.at

Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (Sponsor: Novartis)

Studien-Koordinatoren:
Dr. Stephan Korn
Universitätsklinik für Urologie
Medizinische Universität Wien
E-Mail: stephan.korn@meduniwien.ac.at

Assoz. Prof. Priv.-Doz. Dr. Isabel Maria Heidegger-Pircher
Nationale Studienkoordinatorin
Department für Urologie
Medizinische Universität Innsbruck
E-Mail: isabel-maria.heidegger@i-med.ac.at

Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Studien-Koordinatoren:
Dr. Stephan Korn
Universitätsklinik für Urologie
Medizinische Universität Wien
E-Mail: stephan.korn@meduniwien.ac.at

Prim. apl. Prof. Dr. Johannes Meran
Barmherzige Brüder Wien
E-Mail: studien@bbwien.at

Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

THOR: A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (Sponsor: Janssen)

Studien-Koordinatoren:
Dr. Stephan Korn
Universitätsklinik für Urologie
Medizinische Universität Wien
E-Mail: stephan.korn@meduniwien.ac.at

Prim. apl. Prof. Dr. Johannes Meran
Barmherzige Brüder Wien
E-Mail: studien@bbwien.at

Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) (Sponsor: MSD)

Studien-Koordinator:
Dr. Stephan Korn
Universitätsklinik für Urologie
Medizinische Universität Wien
E-Mail: stephan.korn@meduniwien.ac.at

TROPICs: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer (Sponsor: GILEAD)

Studien-Koordinatoren:
Dr. Stephan Korn
Universitätsklinik für Urologie
Medizinische Universität Wien
E-Mail: stephan.korn@meduniwien.ac.at

Prim. apl. Prof. Dr. Johannes Meran
Barmherzige Brüder Wien
E-Mail: studien@bbwien.at

Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Clinical Protocol CA017078: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (Sponsor: BMS)

Studien-Koordinatoren:
Dr. Stephan Korn
Universitätsklinik für Urologie
Medizinische Universität Wien
E-Mail: stephan.korn@meduniwien.ac.at

Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer (Sponsor: Amgen)

Studien-Koordinatoren:
Dr. Stephan Korn
Universitätsklinik für Urologie
Medizinische Universität Wien
E-Mail: stephan.korn@meduniwien.ac.at

Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL) (Sponsor: Bayer)

Studien-Koordinatoren:
Dr. Stephan Korn
Universitätsklinik für Urologie
Medizinische Universität Wien
E-Mail: stephan.korn@meduniwien.ac.at

Dr. Michael Lotterstätter
Prim. Univ.-Prof. Dr. Stephan Madersbacher, FEBU
Fellow of the European Board of Urology
Abteilung für Urologie und Andrologie, Wien
E-Mail: Michael.Lotterstaetter@gesundheitsverbund.at
E-Mail: Stephan.Madersbacher@gesundheitsverbund.at

PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) EudraCT number: HC1119-CS-03/ 2019-001144-22

Studien-Koordinator:
OA Dr. Michael Ladurner, FEBU
Univ. Klinik für Urologie
Universitätsklinik Innsbruck
E-Mail: michael.ladurner@tirol-kliniken.at

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

Studien-Koordinator:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2) (Sponsor: Janssen)

Studien-Koordinatoren:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Univ.-Prof. Dr. Lukas Lusuardi
Uniklinikum Salzburg (SALK)
Universitätsklinik für Urologie & Andrologie
E-Mail: l.lusuardi@salk.at

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) (Sponsor: Exelixis)

Studien-Koordinator:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (Sponsor: MSD)

Studien-Koordinator:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Prospektive Studie zum Vergleich von Mikro-Ultraschall und MRT für die Detektion eines Prostatakarzinoms

Studien-Koordinator:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Prostate Cancer Outcomes – Compare & Reduce Variation in DKG-zertifizierten Prostatakrebszentren

Studien-Koordinator:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

ADAM: A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (Uniklinikum Münster)

Studien-Koordinatoren:
Assoz. Prof. Priv.-Doz. Dr. Isabel Maria Heidegger-Pircher
Nationale Studienkoordinatorin
Department für Urologie
Medizinische Universität Innsbruck
E-Mail: isabel-maria.heidegger@i-med.ac.at

Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Priv.-Doz. Dr. Thomas Kunit
Uniklinikum Salzburg (SALK)
Universitätsklinik für Urologie & Andrologie
E-Mail: t.kunit@salk.at

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer(VOLGA) (Sponsor: AstraZeneca)

Studien-Koordinatoren:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Univ.-Prof. Dr. Lukas Lusuardi
Uniklinikum Salzburg (SALK)
Universitätsklinik für Urologie & Andrologie
E-Mail: l.lusuardi@salk.at

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects with De Novo or Treatment Emergent Neuroendocrine Prostate Cancer (Sponsor: Amgen)

Studien-Koordinator:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Characterised by PTEN deficiency (CAPItello-281) (Sponsor: AstraZeneca)

Studien-Koordinatoren:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Priv.-Doz. Dr. Thomas Kunit
Uniklinikum Salzburg (SALK)
Universitätsklinik für Urologie & Andrologie
E-Mail: t.kunit@salk.at

A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (Sponsor: Urogen Pharma)

Voraussichtlicher Start:
4. Quartal 2022

Studien-Koordinator:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer (Sponsor: Steba Biotech)

Voraussichtlicher Start:
4. Quartal 2022

Studien-Koordinator:
Prim. Dr. Wolfgang Loidl
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie & Andrologie
E-Mail: wolfgang.loidl@ordensklinikum.at

Studie sucht Patient – Patient sucht Studie

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (Sponsor: Novartis)

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

THOR: A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (Sponsor: Janssen)

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) (Sponsor: MSD)

TROPICs: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer (Sponsor: GILEAD)

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer (Sponsor: Amgen)

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL) (Sponsor: Bayer)

PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) EudraCT number: HC1119-CS-03/ 2019-001144-22

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2) (Sponsor: Janssen)

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) (Sponsor: Exelixis)

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (Sponsor: MSD)

Prospektive Studie zum Vergleich von Mikro-Ultraschall und MRT für die Detektion eines Prostatakarzinoms

Prostate Cancer Outcomes – Compare & Reduce Variation in DKG-zertifizierten Prostatakrebszentren

ADAM: A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (Uniklinikum Münster)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects with De Novo or Treatment Emergent Neuroendocrine Prostate Cancer (Sponsor: Amgen)

A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (Sponsor: Urogen Pharma)

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer (Sponsor: Steba Biotech)

Corona-Impfpflicht: außer Spesen nichts gewesen

Krankenversicherung erwartet für heuer 344 Millionen Verlust

EU-Kommission stößt Debatte über neue Regeln für Blut- und Gewebespenden an

Studie sucht Patient – Patient sucht Studie

PSMAddition: An International Prospective Open-label, ­Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic ­Hormone ­Sensitive Prostate Cancer (mHSPC) (Sponsor: Novartis)

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

THOR: A Phase 3 Study of Erdafitinib Compared With ­Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (Sponsor: Janssen)

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) (­Sponsor: MSD)

TROPICs: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in ­Subjects with Metastatic or Locally Advanced Unresec­table Urothelial Cancer (Sponsor: GILEAD)

A Phase 1 Study Evaluating the Safety, Tolerability, ­Pharmacokinetics, and Efficacy of Prostate Specific ­Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer (Sponsor: Amgen)

A Study in Which Non-metastatic Castration-resistant ­Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL) (Sponsor: Bayer)

PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 versus Enzalutamide in Metastatic ­Castration-Resistant Prostate Cancer (mCRPC) EudraCT number: HC1119-CS-03/ 2019-001144-22

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

A Study of TAR-200 in Combination With Cetrelimab V­ersus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the ­Bladder (SunRISe-2) (Sponsor: Janssen)

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) (Sponsor: Exelixis)

Study of Pembrolizumab (MK-3475) Combination ­Therapies in Metastatic Castration-Resistant Prostate ­Cancer (MK-3475-365/KEYNOTE-365) (Sponsor: MSD)

Prospektive Studie zum Vergleich von Mikro-Ultraschall und MRT für die Detektion eines Prostatakarzinoms

Prostate Cancer Outcomes – Compare & Reduce Variation in DKG-zertifizierten Prostatakrebszentren

ADAM: A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy­ (Uniklinikum Münster)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects with De Novo or Treatment Emergent Neuroendocrine Prostate Cancer (Sponsor: Amgen)

A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (Sponsor: Urogen Pharma)

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer (Sponsor: Steba Biotech)

Das könnte Sie auch interessieren:

Corona-Impfpflicht: außer Spesen nichts gewesen

Krankenversicherung erwartet für heuer 344 Millionen Verlust

EU-Kommission stößt Debatte über neue Regeln für Blut- und Gewebespenden an

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (Sponsor: Novartis)

THOR: A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (Sponsor: Janssen)

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) (Sponsor: MSD)

TROPICs: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer (Sponsor: GILEAD)

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer (Sponsor: Amgen)

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL) (Sponsor: Bayer)

PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) EudraCT number: HC1119-CS-03/ 2019-001144-22

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2) (Sponsor: Janssen)

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (Sponsor: MSD)

ADAM: A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (Uniklinikum Münster)